"The most valuable conversation is the one before the next digital investment approval."
Principal advisory for pharmaceutical and biotechnology manufacturers making digital investment decisions — at the moment of approval, and long after go-live — across Asia, Europe, and Australia.
Seven cases. One pattern. The same gap in every one.
Across pharmaceutical and biotechnology digital investments of every size, in every region — from greenfield biologics plants to multi-country ERP rollouts — the level a digital investment reaches is determined before the first system is selected. Not after the last one goes live. Every case in this book illustrates the same structural gap.
Start with the end in mind. Before any digital investment is approved, the decision-maker should be able to describe clearly how the system will help the business after go-live — not only that it will work. In most organisations described, that question was never asked.
It is all about the business. Digital investment creates no value by itself. A validated system that proves compliance is the minimum. The ceiling is determined by what the organisation does with the data the system generates.
One question at a time, at the right moment. The FC Model™ provides three diagnostic questions — one for each level of maturity. They take minutes to answer honestly, and they change what gets designed for the next five years.
A language for digital investment decisions
The FC Model™ maps organisational maturity across two axes: three levels of maturity, and three dimensions of value. Every digital investment sits somewhere on this map. The FC Model™ tells you where — and what it would take to reach the next level.
| Customer Value | Product Value | Operational Value | |
|---|---|---|---|
| Level 1 Compliant Systems validated. Risk managed. Standards met. |
Supply reaches customers to specification. Delivery reliability is tracked and auditable.
"We can prove we delivered what we promised."
|
Products consistently meet validated quality standards. Quality is demonstrated, not assumed.
"We can prove our products meet the standard we validated."
|
Systems are validated, change-controlled, and defensible. Operations are documented and repeatable.
"We can pass an inspection today."
|
| Level 2 Capable Systems integrated. Decisions evidence-based. |
Customer requirements actively shape manufacturing and commercial decisions. Issues surface before they reach customers.
"Our operations respond to what customers need, not just what the contract specifies."
|
Operating data drives product improvement. Quality is built into the process, not tested in at the end.
"Our products are getting better because of what our systems tell us."
|
Systems integrate across the organisation. Decisions are faster and more evidence-based than before.
"Our systems make us measurably more capable than we were before."
|
| Level 3 Competitive Systems create the advantage. Transformation is how you operate. |
Operating reliability is a source of customer loyalty and competitive differentiation. Customers choose you because of how you operate.
"Our operations create customer value our competitors cannot easily replicate."
|
Product innovation is systematically enabled by operating intelligence. Each cycle generates knowledge that improves the next.
"Our products improve faster than the industry norm because of how our systems learn."
|
Productivity improvement is continuous and measurable. The organisation learns from every system decision.
"We are more productive than our peers and we know exactly why."
|
Three diagnostic questions
Seven cases. One pattern. Freely given to the industry.
Four Level 1 cases. Two Level 2. One Level 3. Each case is real, drawn from direct experience across pharmaceutical and biotechnology organisations in Asia, Europe, and Australia. All organisations are anonymised.
This book exists to change one conversation — the one that happens before a digital investment is approved. It is available freely to the industry in its original form.
Three ways to engage
The practice works through three engagement types, each designed for a specific moment in the decision cycle. All engagements are principal-led — no associates, no delegation to junior staff.
Strategic Advisory Retainer
For organisations navigating complex IT decisions over time. A retained relationship providing continuous access to principal-level judgment — before, during, and after investment approvals.
Diagnostic Engagement
For specific problems requiring a structured analysis and clear recommendation. An FC Model™ diagnostic of your current digital landscape, with a written assessment and action priorities.
Critical Moment Support
For regulatory inspections, MES go-live failures, and time-sensitive situations where experienced judgment is needed immediately. Available with short notice.
Sharing the pattern with the industry
Speaking engagements and conference sessions are an extension of the advisory practice — opportunities to share the patterns from the book and the FC Model™ with pharmaceutical and biotechnology leaders at critical decision moments.
Speaking enquiries →The most valuable moment to use this book is just before the next digital investment approval.
If your organisation is facing a digital investment decision — or is past go-live and uncertain what the integrated data is telling you — a first conversation takes thirty minutes.